Page last updated: 2024-09-05

orantinib and Islet Cell Tumor, Malignant

orantinib has been researched along with Islet Cell Tumor, Malignant in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bergers, G; Bergsland, E; Hanahan, D; Meyer-Morse, N; Song, S	1

Other Studies

1 other study(ies) available for orantinib and Islet Cell Tumor, Malignant

Article	Year
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. The Journal of clinical investigation, 2003, Volume: 111, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carcinoma, Islet Cell; Endothelium, Vascular; Female; Indoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Oxindoles; Pericytes; Platelet-Derived Growth Factor; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor	2003

Article

Year

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

The Journal of clinical investigation, 2003, Volume: 111, Issue:9

Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carcinoma, Islet Cell; Endothelium, Vascular; Female; Indoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Oxindoles; Pericytes; Platelet-Derived Growth Factor; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor

2003